PND23 - Projecting the Potential Cost Effectiveness of Ocrelizumab Versus Standard Care in Primary Progressive Multiple Sclerosis Patients Under Alternative Pricing Scenarios. - Suh, K; Carlson, JJ; Garrison, LP (Value in Health, 2016)